Researchers have identified a protein that powers the virulence of the bacteria that causes gonorrhea, opening the possibility of a new target for antibiotics and, even better, a vaccine.
The findings, published today in PLOS Pathogens, are especially important since the microbe, Neisseria gonorrhoeae, is considered a “superbug” because of its resistance to all classes of antibiotics available for treating infections.
Gonorrhea, a sexually transmitted disease that results in 78 million new cases worldwide each year, is highly damaging if untreated or improperly treated.
It can lead to endometritis, pelvic inflammatory disease, ectopic pregnancy, epididymitis and infertility. Babies born to infected mothers are at increased risk of blindness.
“The infections very often are silent,” said Oregon State University researcher Aleksandra Sikora. “Up to 50 percent of infected women don’t have symptoms, but those asymptomatic cases can still lead to some very severe consequences for the patient’s reproductive health, miscarriage or premature delivery.”
The need for better antibiotic therapy, and a vaccine, is pressing. N. gonorrhoeae strains resistant to the last effective treatment options have emerged, and failures in treatment are occurring.
Sikora and her research team at the OSU/OHSU College of Pharmacy and Ann Jerse’s lab at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, collaborated to discover a novel lipoprotein that N. gonorrhoeae uses to defeat the body’s first line of innate immune defense.
The body relies on enzymes known as lysozymes that, as their name suggests, thwart bacteria by causing their cell wall to lyse, or break apart. Lysozymes are abundant both in epithelial cells, which make up the tissue on the outside of organs and the inside of body cavities, and in the phagocytic cells that protect the body by ingesting foreign particles and bacteria.
In turn, many gram-negative bacteria – characterized by their cell envelope that includes a protective outer membrane – have developed ways of defeating lysozymes. Prior to the work by Sikora’s team, however, only one lysozyme-fighting protein had been discovered in the Neisseria genus.
Now that new targets have been identified, they can be explored as bullseye candidates for new antibiotics or a vaccine – if the lysozyme inhibitor can itself be inhibited, then the bacteria’s infection-causing ability is greatly reduced.
Sikora and her collaborators named the new protein SliC, short for surface-exposed lysozyme inhibitor of c-type lysozyme.
Studying SliC’s function in culture as well as in a gonorrhea mouse model – mice were infected with N. gonorrhoeae, then checked for SliC expression at one, three and five days – researchers determined the protein was essential to bacterial colonization because of its anti-lysozyme role.
“This is the first time an animal model has been used to demonstrate a lysozyme inhibitor’s role in gonorrhea infection,” Sikora said. “Together, all of our experiments show how important the lysozyme inhibitor is. This is very exciting.”
The Latest on: Gonorrhea
via Google News
The Latest on: Gonorrhea
- Taking This Common Antibiotic After Sex Might Help Prevent STDson August 1, 2022 at 9:42 am
A new study claims a common antibiotic can help prevent STDs, which have been on the rise following the pandemic.
- Post-Exposure Doxycycline Reduces STIson July 29, 2022 at 2:19 pm
Among the 327 participants taking pre-exposure prophylaxis (PrEP) to prevent human immunodeficiency virus (HIV), new sexually transmitted diseases (STDs) occurred in 32% of those in the control arm ...
- Gonorrhea Therapeutics Market Latest Trends, Size, Key Players, Revenue and Forecast 2028on July 27, 2022 at 10:32 pm
The MarketWatch News Department was not involved in the creation of this content. Jul 28, 2022 (Heraldkeepers) -- The Global Gonorrhea Therapeutics Market is forecasted to register a CAGR close to 5% ...
- Sexually transmitted diseases rise rapidly as precautions waneon July 27, 2022 at 5:55 am
Overshadowed by the monkeypox outbreak, sexually transmitted diseases are on the rise in Massachusetts and across the country.
- Did Gonorrhea Give Us Grandparents?on July 24, 2022 at 2:02 am
Researchers have identified a set of genetic mutations that protect against cognitive decline in older adults. A new study suggests the selective pressure from infectious pathogens like gonorrhea may ...
- Monkeypox virus could become entrenched as new STD in the USon July 22, 2022 at 5:22 pm
The spread of monkeypox in the U.S. could represent the dawn of a new sexually transmitted disease, though some health officials say the virus that causes pimple-like bumps might yet be contained ...
- GONORRHEA AND INFERTILITY (Part 2)on July 22, 2022 at 5:00 pm
Last week, we started a topic on Gonorrhea and Infertility. We discussed the causes, risks, signs and symptoms. This week, we will discuss effects on fertility, prevention, give advice on what to ...
- Gonorrhea bacteria may have driven the evolution of gene variants that protect older adults against dementiaon July 19, 2022 at 4:44 pm
The findings suggest selective pressure from infectious pathogens like gonorrhea may have promoted the emergence of this gene variant in Homo sapiens, and inadvertently supported the existence of ...
- Grandparents may hold a surprising evolutionary benefit — sparked by gonorrheaon July 19, 2022 at 10:19 am
Researchers from the University of California San Diego School of Medicine have discovered a set of human gene mutations that prevent cognitive decline and dementia in older adults.
via Bing News